Laihui Luo

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience

Laihui Luo, Yongqiang Xiao, Guoqing Zhu et al. · Frontiers in Oncology · 2022 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma

Yongzhu He, Laihui Luo, Renfeng Shan et al. · Journal of the National Comprehensive Cancer Network · 2023 · 36 citations · Full text

Medicine, Oncology, Surgery +14

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

Laihui Luo, Yongzhu He, Guoqing Zhu et al. · Journal of Hepatocellular Carcinoma · 2022 · 31 citations · Full text

Medicine, Surgery, Hepatology +11

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab

Yongqiang Xiao, Guoqing Zhu, Jin Xie et al. · Journal of Hepatocellular Carcinoma · 2023 · 17 citations · Full text

Medicine, Hematology, Oncology +13

AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway

Guoqing Zhu, Laihui Luo, Yongzhu He et al. · Molecular Carcinogenesis · 2024 · 15 citations · Full text

Medicine, Cancer Biology, Oncology +16